Preliminary experience with inhaled milrinone in cardiac surgery

Yoan Lamarche, Louis P. Perrault, Simon Maltais, Karine Tétreault, Jean Lambert, André Y. Denault

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background: Inhaled administration of milrinone reduces pulmonary artery pressure. Pulmonary hypertension (PH) and right heart failure are associated with difficult separation from cardiopulmonary bypass (CPB). Therefore, inhaled milrinone could facilitate separation from CPB. Objective: To determine the impact and timing of administration of inhaled milrinone. Methods: A retrospective analysis of our experience on high-risk patients receiving inhaled milrinone was conducted to evaluate the postoperative course after administration of the drug. Results: Seventy-three patients received inhaled milrinone from June 2002 to February 2005. Mean age was 64 ± 13 years, with a mean preoperative Parsonnet score of 27 ± 14. Inhaled milrinone (5 mg) was administered before (n = 30) or after (n = 40) CPB, three patients had off-pump procedures and were excluded. CPB time was 145 ± 78 min with cross-clamping times of 91 ± 56 min without any significant difference between groups. Fifty-four patients (74%) had difficult separation from CPB, 14 patients (19%) required an intra-aortic balloon pump and 10 patients (14%) needed emergency reinitiation of CPB for hemodynamic instability. Ten patients died in the perioperative period (13.7%). Patients receiving inhaled milrinone prior to CPB initiation had a lowering pulmonary artery pressure after CPB (p < .01) and had less emergency reinitiation of CPB after weaning (3% vs 23%, p = .02) as compared to those with administration after CPB. No detectable side effects were directly linked to the administration of the drug. Conclusion: In this high-risk cohort, use of inhaled milrinone was well tolerated. Administration before initiation of CPB could help weaning from CPB.

Original languageEnglish (US)
Pages (from-to)1081-1087
Number of pages7
JournalEuropean Journal of Cardio-thoracic Surgery
Volume31
Issue number6
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Milrinone
Cardiopulmonary Bypass
Thoracic Surgery
Weaning
Pulmonary Artery
Emergencies
Pressure
Perioperative Period
Pulmonary Hypertension
Constriction
Pharmaceutical Preparations

Keywords

  • Cardiopulmonary bypass
  • Milrinone
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Preliminary experience with inhaled milrinone in cardiac surgery. / Lamarche, Yoan; Perrault, Louis P.; Maltais, Simon; Tétreault, Karine; Lambert, Jean; Denault, André Y.

In: European Journal of Cardio-thoracic Surgery, Vol. 31, No. 6, 01.06.2007, p. 1081-1087.

Research output: Contribution to journalArticle

Lamarche, Y, Perrault, LP, Maltais, S, Tétreault, K, Lambert, J & Denault, AY 2007, 'Preliminary experience with inhaled milrinone in cardiac surgery', European Journal of Cardio-thoracic Surgery, vol. 31, no. 6, pp. 1081-1087. https://doi.org/10.1016/j.ejcts.2007.02.019
Lamarche, Yoan ; Perrault, Louis P. ; Maltais, Simon ; Tétreault, Karine ; Lambert, Jean ; Denault, André Y. / Preliminary experience with inhaled milrinone in cardiac surgery. In: European Journal of Cardio-thoracic Surgery. 2007 ; Vol. 31, No. 6. pp. 1081-1087.
@article{1ba61fa67f9a4d5f9bc02a9cd75bb2d6,
title = "Preliminary experience with inhaled milrinone in cardiac surgery",
abstract = "Background: Inhaled administration of milrinone reduces pulmonary artery pressure. Pulmonary hypertension (PH) and right heart failure are associated with difficult separation from cardiopulmonary bypass (CPB). Therefore, inhaled milrinone could facilitate separation from CPB. Objective: To determine the impact and timing of administration of inhaled milrinone. Methods: A retrospective analysis of our experience on high-risk patients receiving inhaled milrinone was conducted to evaluate the postoperative course after administration of the drug. Results: Seventy-three patients received inhaled milrinone from June 2002 to February 2005. Mean age was 64 ± 13 years, with a mean preoperative Parsonnet score of 27 ± 14. Inhaled milrinone (5 mg) was administered before (n = 30) or after (n = 40) CPB, three patients had off-pump procedures and were excluded. CPB time was 145 ± 78 min with cross-clamping times of 91 ± 56 min without any significant difference between groups. Fifty-four patients (74{\%}) had difficult separation from CPB, 14 patients (19{\%}) required an intra-aortic balloon pump and 10 patients (14{\%}) needed emergency reinitiation of CPB for hemodynamic instability. Ten patients died in the perioperative period (13.7{\%}). Patients receiving inhaled milrinone prior to CPB initiation had a lowering pulmonary artery pressure after CPB (p < .01) and had less emergency reinitiation of CPB after weaning (3{\%} vs 23{\%}, p = .02) as compared to those with administration after CPB. No detectable side effects were directly linked to the administration of the drug. Conclusion: In this high-risk cohort, use of inhaled milrinone was well tolerated. Administration before initiation of CPB could help weaning from CPB.",
keywords = "Cardiopulmonary bypass, Milrinone, Pulmonary hypertension",
author = "Yoan Lamarche and Perrault, {Louis P.} and Simon Maltais and Karine T{\'e}treault and Jean Lambert and Denault, {Andr{\'e} Y.}",
year = "2007",
month = "6",
day = "1",
doi = "10.1016/j.ejcts.2007.02.019",
language = "English (US)",
volume = "31",
pages = "1081--1087",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Preliminary experience with inhaled milrinone in cardiac surgery

AU - Lamarche, Yoan

AU - Perrault, Louis P.

AU - Maltais, Simon

AU - Tétreault, Karine

AU - Lambert, Jean

AU - Denault, André Y.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Background: Inhaled administration of milrinone reduces pulmonary artery pressure. Pulmonary hypertension (PH) and right heart failure are associated with difficult separation from cardiopulmonary bypass (CPB). Therefore, inhaled milrinone could facilitate separation from CPB. Objective: To determine the impact and timing of administration of inhaled milrinone. Methods: A retrospective analysis of our experience on high-risk patients receiving inhaled milrinone was conducted to evaluate the postoperative course after administration of the drug. Results: Seventy-three patients received inhaled milrinone from June 2002 to February 2005. Mean age was 64 ± 13 years, with a mean preoperative Parsonnet score of 27 ± 14. Inhaled milrinone (5 mg) was administered before (n = 30) or after (n = 40) CPB, three patients had off-pump procedures and were excluded. CPB time was 145 ± 78 min with cross-clamping times of 91 ± 56 min without any significant difference between groups. Fifty-four patients (74%) had difficult separation from CPB, 14 patients (19%) required an intra-aortic balloon pump and 10 patients (14%) needed emergency reinitiation of CPB for hemodynamic instability. Ten patients died in the perioperative period (13.7%). Patients receiving inhaled milrinone prior to CPB initiation had a lowering pulmonary artery pressure after CPB (p < .01) and had less emergency reinitiation of CPB after weaning (3% vs 23%, p = .02) as compared to those with administration after CPB. No detectable side effects were directly linked to the administration of the drug. Conclusion: In this high-risk cohort, use of inhaled milrinone was well tolerated. Administration before initiation of CPB could help weaning from CPB.

AB - Background: Inhaled administration of milrinone reduces pulmonary artery pressure. Pulmonary hypertension (PH) and right heart failure are associated with difficult separation from cardiopulmonary bypass (CPB). Therefore, inhaled milrinone could facilitate separation from CPB. Objective: To determine the impact and timing of administration of inhaled milrinone. Methods: A retrospective analysis of our experience on high-risk patients receiving inhaled milrinone was conducted to evaluate the postoperative course after administration of the drug. Results: Seventy-three patients received inhaled milrinone from June 2002 to February 2005. Mean age was 64 ± 13 years, with a mean preoperative Parsonnet score of 27 ± 14. Inhaled milrinone (5 mg) was administered before (n = 30) or after (n = 40) CPB, three patients had off-pump procedures and were excluded. CPB time was 145 ± 78 min with cross-clamping times of 91 ± 56 min without any significant difference between groups. Fifty-four patients (74%) had difficult separation from CPB, 14 patients (19%) required an intra-aortic balloon pump and 10 patients (14%) needed emergency reinitiation of CPB for hemodynamic instability. Ten patients died in the perioperative period (13.7%). Patients receiving inhaled milrinone prior to CPB initiation had a lowering pulmonary artery pressure after CPB (p < .01) and had less emergency reinitiation of CPB after weaning (3% vs 23%, p = .02) as compared to those with administration after CPB. No detectable side effects were directly linked to the administration of the drug. Conclusion: In this high-risk cohort, use of inhaled milrinone was well tolerated. Administration before initiation of CPB could help weaning from CPB.

KW - Cardiopulmonary bypass

KW - Milrinone

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=34248366457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248366457&partnerID=8YFLogxK

U2 - 10.1016/j.ejcts.2007.02.019

DO - 10.1016/j.ejcts.2007.02.019

M3 - Article

VL - 31

SP - 1081

EP - 1087

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 6

ER -